





# Horizon-Miss-2022-Cancer-01-02: Strenghthening research capacities of Comprehensive Cancer Infrastructures



Giovanni Apolone Scientific Director INT – Milano President Elect OECI - Brussels

November 7, 2022

### Disclosure



No economic, financial or personal conflicts of interest

 Scientific Director of INT, a CCC receiving several funds from national and international entities to support institutional studies

#### Outline

- The European scenario
  - unacceptable variability
- EBCP and CM
- Defining Comprehensiveness
  - The OECI vision
- CCI4EU
  - Background
  - The Project

### Cancer in Europe


Epidemiology: 2.7 million new cases (2020), 1.3 million deaths (2020), expected increase of about 25% by 2035


Variability in Epidemiology, Economics and Outcomes


#### **EPIDEMIOLOGY OF CANCER**


Age standardised incidence and mortality rates for all cancers for men and women in Europe 2018 (excluding non-melanoma skin cancers)

J. Ferlay et al. Eur. J Cancer, 2018









## Variability in health expenditures




Figure 7.3. Health expenditure as a share of GDP, 2018 (or nearest year)

Note: Expenditure excludes investments, unless otherwise stated.


1. Australia expenditure estimates exclude all expenditure for residential aged care facilities in welfare (social) services. 2. Includes investments. Source: OECD Health Statistics 2019, WHO Global Health Expenditure Database.

StatLink https://doi.org/10.1787/888934016816

# Variability in purchasing power

GfK Purchasing Power Europe 2017





### Intra-country variability in outcomes (Italy)

#### Net 5-year survival by Italian geographic areas



Variability across the 21 Italian regions, with a North-Center-South trend

	Cancers							_
1	Regions	Tutti i tumori (M)	Tutti i tumori (F)	Colon-retto	Mammella	Prostata	Polmone	Stomaco
NORD	Liguria	51%	61%	61%	87%	90%	15%	26%
	Lombardia	54%	63%	66%	87%	93%	18%	34%
	Piemonte	53%	63%	64%	88%	92%	14%	30%
	Valle d Aosta	61%	64%	68%	88%	94%	12%	36%
	Emilia Romagna	56%	65%	69%	89%	92%	18%	33%
	Friuli Venezia Giulia	53%	61%	64%	88%	95%	12%	32%
	Trentino Alto Adige	53%	63%	66%	87%	91%	16%	36%
	Veneto	55%	64%	65%	88%	93%	16%	32%
	Lazio*							
CENTRO	Marche*							
	Toscana	56%	65%	68%	88%	92%	16%	32%
	Umbria	54%	63%	67%	86%	92%	16%	37%
	Abruzzo*							
	Basilicata	55%	62%	63%	88%	89%	13%	30%
Щ	Calabria	54%	63%	60%	85%	86%	13%	26%
SUD E ISOLE	Campania	50%	59%	59%	84%	89%	13%	31%
ID E	Molise*							
SL	Puglia	52%	61%	61%	85%	89%	15%	28%
	Sardegna	49%	60%	58%	85%	83%	13%	27%
	Sicilia	52%	60%	60%	85%	89%	14%	26%

### European actions against cancer

Cancer Mission


Two initiatives, with some overlapping

• Europe's Beating Cancer Plan

Horizone Europe

Calls to implement EBCP and CM

### **Cancer Mission**



13 bold recommendations

#### Recommendation 10

#### **Recommandation 10:**

Set up a Network of Comprehensive Cancer Infrastructures within and across all EU Member States to increase quality of research and care ...

# Recommendation 10 (2)

... linking recognised national CCC and networks in each member States to establish and European CCI Network

... increasing the number of cancer patients treated into 90%.


### About CCC and CCI

In the literature there are different definitions

In EU calls also (see CRANE and CCI4EU)

 Some reflections are needed about the concept of «comprehensiveness» when declined to CC, CN and CI

# Comprehensiveness



### The OECI mission

```
OECI has the objective to reduce mortality, morbidity and improve survival and quality of life of cancer patients ...

... promoting and enhancing the concepts of "comprehensiveness" and "multidisciplinarity" ...

... supporting programs of "quality" improvement in cancer care ..

... involving our Members in our Working Groups ... and in European calls ...

... favoring synergies with other Cancer Organizations ...

... offering a well structured Accreditation & Designation Programme
```

### The OECI definition of CCC



#### Comprehensiveness: an operational OECI definition

- •In the literature there are several definitions of what defines a comprehensive cancer centre
- •All involve the tripod of clinical care, cancer research and education, well integrated
- •Comprehensive Cancer Centres are designed to bring together leading clinical expertise across all major cancer types with attention to multi-disciplinarity, translational research and education
- •Generic definitions are not sufficient to identify, evaluate and certify comprehensiveness



The need to have measurable evidence (standards) has generated the

**OECI ACCREDITATION AND DESIGNATION Programme** 

#### Organisation of European Cancer Institutes - EEIG

# The OECI A&D Program

OECI Designation Criteria	CANCER CENTRE	OMPREHENSIVE) Cancer Centre	
Organisation & governance. Covers radiotherapy, medical & surgical oncology. Multidisciplinarity, quality system, clinical pathways, education, research org., integration etc.	Qualitative assessment	Qualitative assessment	
Budget for oncology health care	>25 M €	>50 M €	
Budget for oncology research		>8 M €	
Number of beds & ambulatory day care beds	>100	>150	
FTE physicians dedicated to cancer	>30	>50	
New cancer patients per year	>1500	>2500	
RESEARCH:	Adequate for CC as assessed by the audit team	Fulfill at least 4 of the 6 following criteria:	
Peer-reviewed scientific publications/year		>125	
Scientific publications with IF >10		>17	
Scientific publications with IF 5 – 10		>50	
Active clinical trials		>75	
Do clinical trials include Early Phase Trials?		Yes	
Number of patients included in prospective interventional trials as a % of new patients		>10%	





#### HORIZON-MISS-2022-CANCER-01-02: Strengthening research capacities of comprehensive cancer infrastructures

Closure: 07.09.2022; Indicative call budget: EUR 10 M; Project size: EUR 10 M; Coordination & Support Action

#### Scope:

- Offer an R&I-centred capacity-building programme to support existing and future comprehensive cancer infrastructures.
- Cooperation with the EU network of comprehensive cancer centres CRANE, being established through Europe's Beating Cancer Plan. Participating countries will be provided with recommendations. Support and roadmap for implementation and transferable best practices will be identified.

#### **Expected outcomes:**

- Research and health policy makers will benefit from support to further develop or set up comprehensive cancer infrastructures, leading to improvement in *research* and access to care.
- Research and healthcare professionals will benefit from a better integration between research and care;
- · Researchers will benefit from innovative infrastructures to perform research and participate in studies.
- Citizens, including patients and their caregivers will have access to screening, diagnostics and treatments, care
  pathways and integrated care. Participation in clinical trials will be facilitated.

Source: European Commission

### A few definions from the call

Please note the difference between CCCs and CCIs

The Mission Board of the FIT assion on Cancer has defined Comprehensive Cancer Infrastructures as 'national or regional infrastructures that provide resources and services to support, improve and integrate cancer care, research, training of care professionals and education for cancer patients, survivors and families/carers.'

Today, the level of development of Comprehensive Cancer Infrastructures and their capacities, such as their digital, research and innovation-related capacities, vary considerably across Member States and Associated Countries, leading to inequalities, in particular in terror of research, quality and access to care.

The Horizon Europe Mission on Cancer will complement the set-up as Member States and several Associated Countries of an EU network of Commensive Cancer Centres that will be established through the Europe's Beating Concer Plan by 2025. The Mission aims to achieve the target of ensuring that 90% of eligible cancer patients have access to Comprehensive Cancer Infrastructures by 2030.

Now, at the best, between 20-40%

Call: HORIZON-MISS-2022-CANCER-01
Topic: HORIZON-MISS-2022-CANCER-01-02

Type of action: HORIZON-CSA

**Project Title:** Comprehensive Cancer Infrastructure in Europe (**CCI4EU**)

#### **Abstract**

Cancer is the second leading cause of death in Europe with an expected increase of about 25% by 2035.

A wide and unacceptable variability in terms of access to research, innovation and quality care exists between and within countries. Possible solutions are an increase in knowledge by funding research, and a more equitable transfer of what we already know to everyone.

Comprehensive Cancer Centers and Comprehensive Cancer Care Networks may be the core of CCIs that deliver quality care and provide resources to improve and integrate care, research and education.

Data already available confirm that the level of "CCI maturity" in Member States is widely different, from some countries lacking CCIs completely.

A European initiative, implemented in all Member States, based on a capacity building programme (CBP), will help reduce inequalities, in the context of other actions ongoing, such as *CRANE*, *JANE* and *UNCAN*.

CBP is a complex intervention that requires multiple and integrated actions delivered to all the relevant stakeholders. CBP will be designed with an inclusive approach, tailored to the baseline status, capable of creating a change and improvement in research and care, with greater integration between them, supported by an education programme. It will operate at various levels: Individuals, Institutions and Systems.

#### The CSA will implement the following steps:

- define CCI Maturity Model including quality indicators;
- profile the CCIs in each MS and a few ACs in terms of CCI presence and levels of maturity; design tailored CBP interventions, giving priority to MSs without any CCI;
- deliver online training courses open to teams in all MSs and ACs, implement targeted onsite interventions;
- scale up and sustain development; disseminate, exploit and report results.

The CSA will maximize impact by bridging with the work of ongoing EU cancer research projects. National focal points will be key informants in making the links between the CSA, the EC and MSs.





**Number of Partners: 55** 


**Number of Countries involved: 32** 

**Total Requested Budget:** 9.984.080,00€













• Submitted: September 7th, 2022

2 applications

Expected decision: December 7th, 2022